{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015168","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.555358+00:00","generated_at":"2026-05-30T01:45:48.673557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"KALA BIO Q3 net loss $9.0M; cash $49.2M; Phase 2b topline due 2Q 2025","bullets":["Net loss $9.0M ($1.93/share) in Q3 2024 vs $8.7M ($3.41) in Q3 2023.","Cash $49.2M as of Sep 30, 2024; funding expected into Q4 2025; includes $3.2M from CIRM.","R&D $5.2M, G&A $4.4M; operating loss $10.0M in Q3 2024.","Phase 2b CHASE trial for PCED enrolling; topline data expected 2Q 2025; five sites in Argentina.","Exploring KPI-012 for LSCD (est. 100k patients); preclinical KPI-014 for inherited retinal diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015168","json":"https://secwatch.observer/filing/0001558370-24-015168.json","markdown":"https://secwatch.observer/filing/0001558370-24-015168.md","text":"https://secwatch.observer/filing/0001558370-24-015168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/0001558370-24-015168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:45:48.673557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}